| 28.2.2005
IDS LTD ACQUIRE SUOMEN BIOANALYTIIKKA
OY (SBA)
CONTACT
:
Dean Hutchinson, Marketing
TELEPHONE
:
(0191) 519 6104
FAX
: (0191) 519 0760
E-MAIL
: deanh@idsltd.com
IDS
Ltd acquire Suomen Bioanalytiikka Oy (SBA)
Immunodiagnostic
Systems Holdings plc (IDS ) (AIM: IDH), a leading
producer of diagnostic testing kits, is pleased to announce
the acquisition of Suomen Bioanalytiikka Oy (“SBA Sciences”)
of Oulu, Finland.
SBA's
core technology is directed to the determination of a
key marker of osteoclast activity, Tartrate Resistant Acid
Phosphatase (TRACP 5b), in serum and plasma. Current
products include ELISA kits for human (“BoneTRAP ®” ),
rat ("RatTRAP™") and mouse ("MouseTRAP™")
forms of TRACP 5b.
The
products represent an extremely innovative and important family
of products that has achieved an impressive degree of success
in the bone research market in a short period of time.
IDS has a successful existing range of bone and
skeletal assays, including market leading vitamin D kits.
The SBA TRACP 5b products are entirely complementary
to those of IDS, and by bringing these together under
one roof, gives IDS the most comprehensive panel
of bone formation, bone resorption and calciotropic hormone
assays available globally.
The
IDS Holdings plc group now comprises IDS Inc in Fountain Hills,
AZ, IDS GmbH in Frankfurt, and SBA in Oulu.
Dr
Roger Duggan, Managing Director of IDS, added: "We
are excited about the acquisition of the bone TRACP 5b
assays, as these represent excellent products to sell
alongside our existing Bone & Skeletal range of products.
In the markets where bone TRACP 5b has been professionally
marketed such as the USA and Germany, it has seen a rapid
and sustained growth in uptake by researchers and clinical
triallists. We believe there is the opportunity to accelerate
sales throughout Germany and the USA, to extend
this success to the other major European and Asian markets,
applying our marketing expertise to penetrate these potentially
lucrative markets. “
SBA
OY will remain operational in Finland as a wholly-owned subsidiary
of IDS where R&D and new product development will continue
for the foreseeable future. IDS will supply the TRACP 5b products
direct from their UK headquarters with immediate effect.
Further
Information:
Further
Financial Information:
Paul
McManus
Associate
Director
Binns
& Co PR Ltd
Telephone:
+44 (0) 207 786 9600
Paul.mcmanus@binnspr.co.uk
www.binnspr.co.uk
|